Celebrating Our Second Unlearniversary

Today marks Unlearn's second birthday - what we fondly call our unlearniversary.

As we celebrate two years as a company, we are thrilled to see how much we've grown and accomplished. We made our first home in a humble 90-square-foot coworking office in downtown San Francisco. The initial team consisted of four friends: co-founders Charles, Jon, and Aaron plus Graham, our first hire, COO, and "business guy."  

Two years later, we've outgrown two coworking offices and decamped to our own real office a block away from Union Square. The office came fully furnished (thanks, Zagster!), but we've also added two new prized possessions, a Portuguese phone booth and a Swiss Nespresso machine.

Our team has also doubled in size over the past year, with the addition of a senior computational biologist, communications specialist, chief commercial officer, and machine learning scientist. As Unlearn grows, we are excited for the opportunity to build a team that reflects the diversity of the patients and scientists we serve and the challenges we hope to solve together. But for us, one of the best parts of growing is having more people at the lunch table - our favorite place to share thoughts about everything under the sun.

Lastly, we reached some key milestones this year. We published several papers, most recently on our Alzheimer's disease model. Our Alzheimer's disease paper attracted some media attention. And to top it all, we recently obtained new funding to continue helping patients and scientists develop new treatments for complex diseases.

We are grateful for the people who have helped us - investors, advisers, and our families and friends - and we are excited to see Unlearn grow even more this coming year.


Your Digital Twin - UnlearnAI


Using AI Digital Twins for Drug Testing


Unlearn.AI nabs $12M to build “digital twins” to speed up and improve clinical trials

“Unlearn’s pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time."
Dr. Charles Fisher, CEO of Unlearn AI, discusses creating digital clones by using artificial intelligence for use in clinical drug trials.
A fascinating approach to the problem of how to make clinical trials more efficient, and understand more about what may be possible with more and better patient data.